Becton, Dickinson and Company (BD), commonly known as BD, has unveiled a strategic collaboration with Techcyte, aiming to revolutionize cervical cancer diagnostics with an artificial intelligence (AI)-based algorithm. This partnership is anticipated to enhance BD's position in the global Integrated Diagnostic Solutions business, falling under its broader Life Sciences arm.
The collaboration centers around the development of an AI-driven algorithm designed to assist cytologists and pathologists in efficiently identifying evidence of cervical cancer and pre-cancer through whole-slide imaging. Techcyte's platform, already CE-marked for clinical use in Europe, is compatible with liquid-based cytology preparations, including BD SurePath Liquid-based Pap Test vials, and several widely used whole-slide imagers in the market.
While the Techcyte system is awaiting FDA approval for clinical use and CE certification to the In Vitro Diagnostic Regulation (IVDR), the BD and Techcyte Integrated Visual Diagnostic Decision (IVDD) solution is set to be commercially available in Europe during the first half of 2024. However, its availability in the United States is contingent on FDA approval for clinical use.
Cervical cancer remains a global health concern, causing over 340,000 fatalities annually. In response, BD envisions reducing the mortality rate through a comprehensive approach, emphasizing effective screening. Despite the healthcare sector shifting towards human papillomavirus (HPV) screening as the primary test for cervical cancer, the company emphasizes the continued importance of Pap tests in the diagnostic process.
The agreement aims to provide a complete solution that mitigates potential human errors and enhances testing efficiency. By incorporating AI-based digital technology, the solution seeks to address the shortage of expert cytologists, streamlining the traditional Pap test and making the diagnostic process more efficient.
Techcyte's digital workflow, supported by an AI-based algorithm, is expected to deliver consistent and accurate results for patients. The partnership aligns with the growing market potential in the HPV testing and Pap test sector, valued at $4.9 billion in 2022 and projected to reach $9.2 billion by 2027 at a CAGR of 13.2%, according to a report by MarketsandMarkets.
Notably, BD's recent collaboration with Hamilton to develop automated applications and receive FDA clearances for the BD MiniDraw Capillary Blood Collection System underscores the company's commitment to advancing diagnostic technologies.
